20-13-42.jpg More Microsoft is once again bundling Solitaire with Windows, but if you want an ad-free experience then that’s going to cost you. The app in question is the Microsoft Solitaire app, and as first reported by, the app prompts users to “upgrade” to the premium version for $1.49 a month (or $9.99 a year) to remove the ads and get some “coins” and “power boosts.” What’s Hot on ZDNet • • • • A similar system existed in Windows 8/8.1, but the game wasn’t bundled with the operating system and was a separate download. With Windows 10 being offered to so many people as a freebie, it’s natural that Microsoft will want to explore other revenue streams. Ads, and paying for their removal, is an obvious revenue stream, but from what I can tell this ad-ladened bundle will also ship with OEM and paid-for copies of Windows 10. So not only do you get to, you also get the adware version of Solitaire. The other advantage for Microsoft is that the more people it can get signed up to the app store with a payment method, the more likely they are to spend.

Download this game from Microsoft Store for Windows 10, Windows 8.1, Windows 10 Mobile, Windows 10 Team (Surface Hub). See screenshots, read the latest customer reviews, and compare ratings for Solitaire Collection +. Read More,Windows 10 comes pre-installed with the Microsoft Solitaire Collection (MSC). Per default, MSC comes with in-app ads. By upgrading to the premium version for $1.49 per month or $10 per year, you can remove advertisements and unlock additional features.

Whether you love this approach or loathe it entirely will come down to personal preference. Some will say that it’s a small price to pay for an entire operating system (assuming they didn’t pay for that operating system in the first place). Others will feel that $1.49 per month or $9.99 a year just to remove ads from an app is pretty steep. And it’s not like Apple isn’t trying to nickel and dime customers with iCloud subscriptions and music subscriptions.

For example, 20GB of extra iCloud storage costs $0.99 a month. I’ve no issue with the ad-based business model, and I feel that the way that the ads are displayed in Solitaire app isn’t overly annoying (it’s just a full-screen when you first load the game). But I also remember the MSN/Windows Live Messenger days and the seizure-inducing ads that program used to display. I wouldn’t like to see those make their way into the Start menu or onto the desktop.

See also: • • • • •. Reuters Chipmaker Nvidia Corp is nearing a deal to acquire peer Mellanox Technologies Ltd for more than $7 billion in cash, a person familiar with the matter said on Sunday.

Mehrobdan chayon filmi. Mehrobdan chayon Saytimizdan nafaqat elektron, balki qog'ozli kitoblarga ham buyurtma berishingiz mumkin. Buyurtmangiz O'zbekiston pochtasi orqali manzilingizga etkaziladi.

The deal would be Nvidia's biggest-ever acquisition and boost its business of making chips for data centers, allowing it to reduce its reliance on the video game industry, for which it is best known as a major technology vendor. Nvidia has outbid Intel Corp in the auction for Mellanox and could announce a deal as early as Monday, the person said. Thomson Reuters StreetEvents Initiatives that we've taken at FLY over the last few years, which is -- include disposing of older and underperforming aircraft, optimizing our capital structure, repurchasing shares at significant discounts to book value and perhaps, most importantly, growing our fleet prudently, have all combined to produce another very positive quarterly financial result and a significant increase in FLY's book value per share. For the quarter, we earned 30 -- $0.94 adjusted earnings per share and produced a 17.8% adjusted return on equity. Both very positive numbers that were based on our 26% growth in operating lease rental revenue, combined with a lower growth in expenses. Thomson Reuters StreetEvents If you turn to Slide 3, our agenda slide, there are really 5 key parts to the Sesen Bio's story that I want to provide an update on today: First, bladder cancer is an area of significant unmet need, and we are seeing strong support for new treatments from regulators, payers, patients and physicians; second, our Phase II and Phase III clinical trials are highly aligned with FDA guidance. We are confident in the probability of regulatory approval, and we look forward to upcoming discussions with the FDA; third, we believe Vicinium has a unique dual mechanism of action, which may position it as a preferred choice for combination therapy with checkpoint inhibitors; fourth, we see the potenti.